Skip to main content

Advertisement

Table 1 Patient demographics

From: [18F]Fluciclovine PET discrimination between high- and low-grade gliomas

Lesion Patient sex Age Histopathology WHO grade Histologic verification (days before PET) Ki-67 (%)
1 F 58 Oligodendroglioma II SB (4 day) 3
2 M 38 Oligodendroglioma II SB (19 day) 3
3 M 56 Diffuse astrocytoma II SB (13 day) 4
4 M 36 Oligodendroglioma II SB (14 day) < 1
5 M 39 Oligodendroglioma II EB (42 day) N/A
6 F 32 Diffuse astrocytoma II EB (61 day) 4
7 M 45 Anaplastic astrocytoma III EB (31 day) 40
8 F 50 Glioblastoma IV SB (7 day) 12
9 M 70 Glioblastoma IV SB (15 day) 40
10a F 72 Glioblastoma IV SB (27 day) 30
11a F 72 Glioblastoma IV SB (27 day) 30
12 M 58 Glioblastoma IV EB (3 day) N/A
13a F 36 Glioblastoma IV EB (13 day) N/A
14a F 36 Glioblastoma IV EB (13 day) N/A
15 F 58 Glioblastoma IV EB (14 day) 10
16 F 65 Glioblastoma IV EB (16 day) 35
17 M 67 Glioblastoma IV EB (13 day) 8
18 F 60 Glioblastoma IV EB (18 day) N/A
  1. SB stereotactic biopsy, EB excisional biopsy/partial resection, N/A not available
  2. aIndicates lesions from the same patient